

## Disclosures

### Personal Commercial (10)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Bayer Healthcare Pharmaceuticals	Research/Research Grants ‡ <i>Bleeding Risk Score</i>	None (\$0)	<i>Prevention</i>
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Prevention</i>
Eli Lilly and Company	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Prevention</i>
Genentech, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Prevention</i>
Idorsia	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>General Cardiology</i>
New Amsterdam	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Prevention</i>
Novartis Corporation	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Prevention</i>
Novo Nordisk Inc.	Research/Research Grants	None (\$0)	<i>Prevention</i>
Novo Nordisk Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Prevention</i>
Siemens	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Acute Coronary Syndromes</i>

### Additional Personal Commercial Disclosures for Education Activities (4)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Agepha	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Stable Ischemic Heart Disease</i>
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Acute Coronary Syndromes</i>
Merck & Co., Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Prevention</i>
Vectura	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Vascular Medicine</i>

### Personal Organizational or Other Non-Commercial (4)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
ACC	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>
American Heart Association	Research/Research Grants	None (\$0)	<i>General Cardiology</i>
FDA	Research/Research Grants	None (\$0)	<i>General Cardiology</i>
National Institutes of Health	Research/Research Grants	None (\$0)	<i>Prevention</i>

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (2)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2024	Cholesterol	Plaintiff ‡ <i>none</i>	Lawsuit on behalf of the US FTC for a product with purported health benefit.	Significant (>= \$5,000)
2024	Diabetes	Defendant ‡ <i>none</i>	Challenge to a patent for a diabetes medication	Significant (>= \$5,000)

## Agreement

---

### **Certified Education Attestation** | Signed on 10/2/2024

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>*

### **Confidentiality, Disclosure and Assignment Agreement** | Signed on 10/2/2024

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

### **Embargo** | Signed on 10/2/2024

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

### **On-Going Obligation Agreement** | Signed on 10/2/2024

---

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.